The efficacy of leuprolide depot in combination with an aromatase inhibitor delivered monthly compared to once every 3 months in premenopausal women with estrogen receptor positiveebreast cancer was assessed in a single-center retrospective study. There was no significant difference between the groups with respect to
Introduction
Leuprolide acetate depot (Lupron) provided as an intramuscular injection is currently used off label for ovarian ablation in premenopausal women with breast cancer with estrogen receptor (ER)-positive disease who are receiving therapy with an aromatase inhibitor. It is an agonist of gonadotropin-releasing hormone (GnRH) and acts as a potent inhibitor of gonadotropin secretion. Continuous administration results in suppression of ovarian steroidogenesis as a result of decreased levels of luteinizing hormone and follicle-stimulating hormone (FSH), with a subsequent decrease in estrogen levels.
1 It is available in many different doses and administration schedules and also carries several US Food and Drug Administration (FDA) indications, including treatment of prostate cancer. However, leuprolide acetate currently does not carry an FDA approval for the treatment of breast cancer. Despite this, there have been several large multicenter randomized controlled trials that have proven that adjuvant treatment of ER-positive breast cancer in premenopausal woman with a GnRH analog is an effective therapy. [2] [3] [4] To our knowledge, there has been no study to date evaluating different administration schedules of leuprolide acetate depot in combination with an aromatase inhibitor as adjuvant treatment in ER-positive breast cancer in premenopausal women. We report the results of a single-institution experience comparing leuprolide depot provided once a month and provided once every 3 months in combination with an aromatase inhibitor in premenopausal women with ER-positive breast cancer.
Methods

Patients
Eligibility for the trial required documented premenopausal status. Inclusion criteria were histologically proven operable breast cancer, and tumor that expressed ER or progesterone receptor in at least 10% of the cells, as assessed by immunohistochemical testing. All patients must have been 18 years of age or older, undergone either a total mastectomy with subsequent optional radiotherapy or breastconserving surgery with subsequent radiotherapy, and received adjuvant ovarian suppression in combination with an aromatase inhibitor for at least 1 year. Women who underwent bilateral oophorectomy or who received ovarian irradiation were excluded.
Design
This study was designed as a retrospective chart review of patients identified from a Cerner-generated report on the basis of administration of leuprolide acetate at the infusion clinic at the Indiana University Melvin and Bren Simon Cancer Center and surrounding infusion centers in Indianapolis. Patients were separated into 2 treatment arms on the basis of a documented physician order according to leuprolide acetate depot administration: one group received 7.5 mg intramuscular injection once a month or 22.5 mg intramuscular injection once every 3 months.
The primary end point was the proportion of patients who experienced ovarian ablation, defined as an estradiol concentration of less than 40 pg/mL and an FSH concentration of 23 to 116 mIU/ mL after 3 months of treatment. Secondary end points included the following: disease-free survival, defined as the time from receiving the first dose of leuprolide acetate depot to the appearance of invasive recurrence of breast cancer (local, regional, or distant), invasive contralateral breast cancer, second (nonbreast) invasive cancer, or death without breast cancer recurrence or second invasive cancer; overall survival, defined as the time from randomization to death from any cause; and safety, defined as the incidence of any grade adverse events reported while receiving treatment. For patients who did not have an end point event, the times were censored 1 year after initial treatment date.
Study Oversight
The trial protocol was designed by the lead author and was approved by the institutional review board at the Indiana University Melvin and Bren Simon Cancer Center in Indianapolis. The first author contributed to the collection of data, statistical analysis, and interpretation of the results. All the authors approved the final version of the report and assume responsibility for adherence to the study protocol and for the accuracy and completeness of the data and analyses reported. No funder had any role in the design, conduct, analysis, or interpretation of the study or in the writing of this report.
Statistical Analysis
The statistical analysis plan for this study was to compare the proportion of patients who experienced ovarian ablation between the 2 groups, with the hypothesis that there would be no difference. Differences in baseline characteristics were analyzed by the Pearson chi-square test for all categorical data and the Student t test for all continuous data. Kaplan-Meier estimates of time-to-event end points were calculated. The log-rank test was used to calculate P values comparing the 2 groups. All tests were 2 sided, and P < .05 was considered statistically significant. The statistical testing was performed by SPSS 21 for Windows (IBM SPSS, Chicago, IL).
Results
Study Population
From January 1, 2015, to October 1, 2016, a total of 201 patients met the eligibility criteria for the study; 100 patients were in the leuprolide 7.5 mg monthly arm and 101 patients in the leuprolide 22.5 mg every 3 months arm. Baseline patient characteristics Leuprolide Administration Schedules are shown in Table 1 . The median age of the patient at the first dose of adjuvant hormone therapy was 40 years. Node-positive disease was present in 37% of patients overall, and in 39% and 35% of the leuprolide monthly and every 3 months arms, respectively. There was no significant difference between groups with respect to age, prior chemotherapy, tumor grade, lymph node involvement, tumor size, human epidermal growth factor receptor 2 (HER2) status, or prior endocrine therapy. The cohort of patients who received prior endocrine therapy had been treated with tamoxifen to assess tolerance to hormone therapy or as a bridge to a GnRH agonist plus aromatase inhibitor.
Efficacy
Three months after the first dose of leuprolide depot, all patients in the 7.5 mg monthly group experienced ovarian ablation, and all but one patient in the 22.5 mg every 3 months group experienced ovarian ablation (P ¼ 1). The distribution of estradiol and FSH levels between the 2 cohorts at 3-month follow-up are reported in Table 2 . At 1-year follow-up, 9 patients had disease recurrence, had second invasive disease, or died. The rate of disease-free survival at 1 year was 95% among patients who received leuprolide 7.5 mg monthly compared to 96% among those who received leuprolide 22.5 mg every 3 months (P ¼ .75) (Figure 1) . Death was reported in 1 patient in the leuprolide 22.5 mg every 3 months group; the difference was not significant.
Adverse Events
After 1-year follow-up of all patients in this study, 95% of patients experienced one or more adverse effects related to treatment with either leuprolide acetate or the aromatase inhibitor. The most common adverse effect reported, according chart review, across both arms was musculoskeletal symptoms (90%) such as arthralgia (Table 3) . Reported adverse effects related to the administration of leuprolide included hot flashes, insomnia, fatigue, depression, and vaginal dryness. These adverse effects were expected following the administration of combination hormone therapy with leuprolide and an aromatase inhibitor based on previous reports.
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Discussion
This study demonstrated that 22.5 mg intramuscular injection of leuprolide acetate once every 3 months is as efficacious and tolerable as the monthly 7.5 mg formulation in combination with an aromatase inhibitor. All but one patient experienced ovarian ablation in the 2 arms by month 3 of treatment. This is comparable to the original research by Boccardo et al, 5 who were the first to evaluate the endocrinologic and clinical activity of a slow-release formulation of leuprolide acetate in breast cancer patients. A total of 50 pre-or perimenopausal patients with early-or late-stage breast cancer who were candidates for endocrine treatment were included in the study and were randomly allocated to receive either 3.75 mg of leuprolide acetate every month or 11.25 mg of leuprolide acetate every 3 months. In all, 23 patients were allocated to the monthly formulation and 27 to the every 3 months formulation. There was no evidence of any difference in clinical outcome or drug-induced adverse effects, with hot flashes being recorded in about 50% of patients in both groups. All endocrine parameters, particularly estradiol levels, were suppressed to a similar extent. These results were validated in our study; however, different doses of leuprolide acetate depot were used, and the study of Boccardo et al did not use combination GnRH agonists with an aromatase inhibitor. Our institution uses the approved prostate cancer doses of leuprolide acetate depot instead of the off-label doses used in the previous study. Previous large-scale randomized controlled trials such as the TABLE study have also used the lower dosage of 11.25 mg leuprolide every 3 months when in combination with tamoxifen versus chemotherapy plus tamoxifen. 2 This leaves an area of uncertainty in terms of which dose of GnRH agonist is optimal, as other trials such as the SOFT/TEXT trials used a different GnRH agonist in the form of triptorelin. Triptorelin was dosed in this study in accordance with the FDA-approved prostate cancer dosing of 3.75 mg provided intramuscularly every 28 days. 3, 4 While there appears to be no difference in disease-free survival, overall survival, or adverse events, these results must be interpreted with caution, as our study was not randomized or stratified for disease stage, chemotherapy received, patient age, disease grade, or HER2 status. The SOFT/TEXT trials solidified GnRH agonists as a definitive option in adjuvant therapy for premenopausal women with ER-positive breast cancer. 3, 4 The primary analysis of the combined data tested the hypothesis that adjuvant therapy with an aromatase inhibitor, exemestane, improved disease-free survival compared to tamoxifen among premenopausal women treated plus ovarian suppression in the form of monthly triptorelin. The results revealed that at 5 years, patients who received exemestane plus ovarian suppression had superior disease-free survival and less recurrence compared to tamoxifen plus ovarian suppression. Because these results were published recently, it was not until 2 years ago that we saw a shift in the prescribing habits of leuprolide acetate depot at our institution. Therefore, we are unable to capture more long-term survival data at 5 years, versus 1 year in our study, of follow-up at this time. Of note, the single patient who did not experience ovarian ablation in the group provided leuprolide once every 3 months had not experienced disease recurrence or death at 1 year follow-up. This patient, however, was only 28 years old. In total, there were 7 patients across both groups who were younger than 30. The study's retrospective design comes with inherent limitations. Our patient population was small, and we describe a singleinstitution experience, not a larger randomized, multicenter trial of adjuvant hormone therapy in breast cancer patients. However, our study was powered to find a significant difference in the primary outcome. There were also some data points that were unable to be captured because we had to rely on documentation in patient charts. Accuracy and documentation of adverse events such as injection-site pain could not be collected because of this. A future randomized prospective study is warranted to confirm the results of this study and to allow for longer follow-up.
Conclusion
In conclusion, leuprolide acetate depot administered every 3 months is as efficacious and tolerable as a monthly injection in combination with an aromatase inhibitor for premenopausal patients with ER-positive breast cancer. Providing 22.5 mg leuprolide acetate depot intramuscularly every 3 months for patients may result in shorter infusion chair time, cost savings, and higher patient satisfaction.
Clinical Practice Points
The SOFT/TEXT trials solidified GnRH agonists as a definitive option in adjuvant therapy for premenopausal women with ERpositive breast cancer; at 5 years, patients who received exemestane plus ovarian suppression has better disease-free survival and less recurrence compared to tamoxifen plus ovarian suppression. When leuprolide 7.5 mg depot administered every month in combination with an aromatase inhibitor was compared to leuprolide 22.5 mg depot administered every 3 months in combination with an aromatase inhibitor, no difference was observed in ovarian suppression after 3 months of treatment. Leuprolide acetate depot in combination with an aromatase inhibitor administered every 3 months is as efficacious and tolerable as a monthly injection for premenopausal patients with HRpositive breast cancer.
